The effect of Resveratrol on the expression of the granulosa apoptosis-associated genes in polycystic ovary syndrome and its relationship with in vitro fertilization outcome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200905048630N1

Enrollment

Registered

2020-09-21

Start date

2020-12-21

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome: PCOS. polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: from the beginning of the cycle, individuals in this group will receive one 99% pure trans-Resveratrol capsule (800 mg per day) as orally purchased from the US co

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women with polycystic ovary syndrome based on Rotterdam criteria Women of childbearing age between 18 and 40 years Candidate for in vitro fertilization Not receiving insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Apoptosis. Timepoint: 40 days after the beginning of the intervention. Method of measurement: real time pcr.	—

Secondary

Measure	Time frame
Egg numbers. Timepoint: 40 days after the beginning of the intervention. Method of measurement: Counting.;Number of embryos. Timepoint: 43 days after the beginning of the intervention. Method of measurement: Counting.;Number of good quality embryo. Timepoint: 43 days after the beginning of the intervention. Method of measurement: Counting.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEnsieh salehi

Bandare-abbas University of Medical Sciences

salehiensieh@gmail.com+98 76 3333 0755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026